Ignacio Matos

4.9k total citations
57 papers, 818 citations indexed

About

Ignacio Matos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ignacio Matos has authored 57 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Ignacio Matos's work include Cancer Immunotherapy and Biomarkers (17 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Genomics and Diagnostics (8 papers). Ignacio Matos is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Genomics and Diagnostics (8 papers). Ignacio Matos collaborates with scholars based in Spain, United States and United Kingdom. Ignacio Matos's co-authors include Elena Garralda, Josep Tabernero, Lipika Goyal, Funda Meric‐Bernstam, Vivek Subbiah, Ben Tran, Jacob J. Adashek, Ishwaria M. Subbiah, Dhakshina Moorthy Ganeshan and Arjun K. Menta and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Ignacio Matos

52 papers receiving 806 citations

Peers

Countries citing papers authored by Ignacio Matos

Since Specialization

Citations

This map shows the geographic impact of Ignacio Matos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Matos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Matos more than expected).

Fields of papers citing papers by Ignacio Matos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Matos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Matos. The network helps show where Ignacio Matos may publish in the future.

Co-authorship network of co-authors of Ignacio Matos

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Matos. A scholar is included among the top collaborators of Ignacio Matos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Matos. Ignacio Matos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis 2024 ·British journal of surgery ·Daniel Aliseda, Jorge Arredondo, (unknown), (unknown), Javier Rodríguez, Ignacio Matos, Fernando Rotellar, Jorge Baixauli, Carlos Pastor	6
2	Fcγ receptors and immunomodulatory antibodies in cancer 2023 ·Nature reviews. Cancer ·Felipe Gálvez‐Cancino, (unknown), (unknown), Ignacio Matos, Danwen Qian, Karl S. Peggs, Kevin Litchfield, Sergio A. Quezada	40
3	Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials 2023 ·The Oncologist ·(unknown), Federico Cappuzzo, Ignacio Matos, Mark A. Socinski, Ashley M. Hopkins, Michael J. Sorich	7
4	Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling 2022 ·Nature Cancer ·Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, (unknown), (unknown), Mansi Shah, Eyal David, (unknown), Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit	41
5	LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer 2021 ·Annals of Oncology ·Zev A. Wainberg, Ignacio Matos, Jean‐Pierre Delord, Philippe A. Cassier, Marta Gil-Martín, (unknown), Patricia LoRusso, Rastilav Bahleda, Antoîne Italiano, Diana Mendus, Tien Hoang, (unknown), Xingqiao Wen, (unknown), Thao D. Pham, Namrata S. Patil, (unknown), Johanna C. Bendell, Andrés Cervantes, (unknown)	15
6	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 2021 ·The Lancet Respiratory Medicine ·Timothy A. Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren, Luana Calabrò, Ronnie Shapira‐Frommer, Bo Gao, Steven Kao, Ignacio Matos, David Planchard, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Hedy L. Kindler	55
7	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407) 2020 ·The Oncologist ·Enrique Grande, Àlex Teulé, Teresa Alonso‐Gordoa, Paula Jiménez‐Fonseca, Marta Benavent, Jaume Capdevila, Ana Custodio, Ruth Vera, (unknown), Adelaida La Casta, Juan J. Díez, Pablo Gajate, Javier Molina‐Cerrillo, Ignacio Matos, Eva Cristóbal, J.C. Ruffinelli, José Palacios, Rocio García‐Carbonero	24
8	572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials 2020 ·Annals of Oncology ·(unknown), (unknown), (unknown), Ignacio Matos, (unknown), (unknown), María Vieito, Irene Braña, (unknown), (unknown), (unknown), (unknown), T. Macarulla Mercadé, Jaume Capdevila, S. Cedrés, Ana Oaknin, Elena Élez, Josep Tabernero, Rodrigo Dienstmann, Elena Garralda	1
9	573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure 2020 ·Annals of Oncology ·(unknown), (unknown), (unknown), Irene Braña, (unknown), Ignacio Matos, María Vieito, (unknown), (unknown), (unknown), M. Díez García, Helena Verdaguer, Carolina Ortiz, (unknown), (unknown), Ana Callejo, (unknown), Josep Tabernero, Rodrigo Dienstmann, Elena Garralda	1
10	442P Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) 2020 ·Annals of Oncology ·Bhumsuk Keam, (unknown), (unknown), Lori J. Wirth, (unknown), Aaron S. Mansfield, Marcia S. Brose, Giuseppe Curigliano, Sophie Leboulleux, Viola W. Zhu, Ignacio Matos, (unknown), Christina S. Baik, G. Lopes, Yann Godbert, Debashis Sarker, (unknown), Christopher D. Turner, Matthew H. Taylor, (unknown)	1
11	Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors 2020 ·Annals of Oncology ·Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal, Ben Tran, Yi He, Ikuo Yamamiya, Karim A. Benhadji, Ignacio Matos, Hendrik‐Tobias Arkenau	107
12	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? 2020 ·Trends in cancer ·Jacob J. Adashek, Ishwaria M. Subbiah, Ignacio Matos, Elena Garralda, Arjun K. Menta, Dhakshina Moorthy Ganeshan, Vivek Subbiah	88
13	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial 2019 ·Molecular Cancer Therapeutics ·Jaume Capdevila, Ignacio Matos, Francesco M. Mancuso, Carmela Iglesias, Paolo Nucíforo, Carles Zafón, Héctor G. Pálmer, (unknown), (unknown), Jorge Hernando, Guillermo Villacampa, Carol E. Peña, Josep Tabernero, Marcia S. Brose, Martin Schlumberger, Ana Vivancos	10
14	Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas 2019 ·Clinical Cancer Research ·Jaume Capdevila, Oriol Arqués, José Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Francesco M. Mancuso, Stefania Landolfi, Jorge Barriuso, Paula Jiménez‐Fonseca, Carlos López, Rocio García‐Carbonero, Jorge Hernando, Ignacio Matos, (unknown), Javier Hernández‐Losa, Manel Esteller, Anna Martínez‐Cardús, Josep Tabernero, Ana Vivancos, Héctor G. Pálmer	28
15	Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results 2019 ·Annals of Oncology ·Ignacio Matos, Lipika Goyal, James M. Cleary, Martin H. Voss, Do‐Youn Oh, (unknown), Cedric Chuan Young Ng, Gopa Iyer, (unknown), Youyou Hu, Anne Vaslin Chessex, (unknown), Valérie Nicolas, (unknown), Claudio Zanna, Keith T. Flaherty, Josep Tabernero, David M. Hyman	4
16	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) 2019 ·British Journal of Cancer ·(unknown), (unknown), Alberto Carmona‐Bayonas, Rocio García‐Carbonero, Ana Custodio, Marta Benavent, Teresa Alonso Gordoa, (unknown), Manuel Sánchez Cánovas, Ignacio Matos, Vicente Alonso, Carlos López, A. Viúdez, (unknown), (unknown), Enrique Grande, Jaume Capdevila, Paula Jiménez‐Fonseca	24
17	Early evolutionary divergence between papillary and anaplastic thyroid cancers 2018 ·Annals of Oncology ·(unknown), Regina Mayor, Francesco M. Mancuso, Carmela Iglesias, Ginevra Caratù, Ignacio Matos, Carles Zafón, Jorge Hernando, A. Petit, Paolo Nucíforo, José Cameselle‐Teijeiro, Clara V. Álvarez, Juan A. Recio, Josep Tabernero, Xavier Matías‐Guiu, Ana Vivancos, Joan Seoane	48
18	Early-drug development in the era of immuno-oncology: are we ready to face the challenges? 2018 ·Annals of Oncology ·María Ochoa de Olza, Marc Oliva, Cinta Hierro, Ignacio Matos, Juan Martín-Liberal, Elena Garralda	20
19	The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors 2017 ·Targeted Oncology ·(unknown), Ignacio Matos, Tamara Saurí, Jorge Hernando, Jaume Capdevila	1
20	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer 2016 ·Expert Opinion on Emerging Drugs ·Ignacio Matos, Élena Elez, Jaume Capdevila, Josep Tabernero	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact